Core Insights - PainReform Ltd. has announced positive safety data from Phase I human studies and preclinical evaluations of its OcuRing™-K platform, which supports its advancement toward Investigational New Drug (IND) submission [1][6] Group 1: Safety and Efficacy - The development program included preclinical rabbit studies and a Phase I clinical study in patients undergoing cataract surgery, demonstrating a favorable safety profile for the OcuRing™-K platform [2] - In the Phase I clinical study, no treatment-emergent adverse events related to the study drug were observed, and all reported adverse events were consistent with cataract surgery expectations [3] - Preclinical studies showed favorable local tolerability with no ocular tissue abnormalities, supporting consistent safety findings across both preclinical and clinical evaluations [4] Group 2: Product Features and Development - OcuRing™-K is designed for targeted, sustained release of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids through a single intraoperative application, utilizing a preservative-free formulation [5] - The company is advancing IND-enabling activities, with preparations underway to support the next phase of clinical evaluation in the United States [6] Group 3: Company Overview - PainReform Ltd. focuses on reformulating established therapeutics for post-operative pain management and aims to improve patient outcomes while reducing reliance on opioids [7]